Pfizer and Sangamo's Gene Therapy Continues to Help Patients with Hemophilia in Clinical TrialThe Motley Fool • 06/18/20
Are Options Traders Betting on a Big Move in Sangamo (SGMO) Stock?Zacks Investment Research • 06/16/20
Sangamo Stock Avoids Biotech Pitfall On Pfizer-Partnered Gene TherapyInvestors Business Daily • 06/11/20
Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/12/20
Is Sangamo Therapeutics (SGMO) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 05/05/20
How to Find Strong Stocks Under $10 to Buy During the Market ComebackZacks Investment Research • 04/14/20
Sangamo Therapeutics: Market Cap Is At A Bargain Relative To Its Cash PositionSeeking Alpha • 03/25/20
Sangamo's Partnership With Biogen Is Only One Big Pharma Partnership Based Off Of PipelineSeeking Alpha • 03/16/20
Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 03/02/20
Sangamo Therapeutics (SGMO) Surpasses Q4 Earnings and Revenue EstimatesZacks Investment Research • 02/28/20
Sangamo Partners With Biogen to Target Alzheimer’s and Parkinson’s Development24/7 Wall Street • 02/27/20
Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological DiseasesGlobeNewsWire • 02/27/20